• Vaccine Name: Salmonella Typhimurium guaBA/clpP/fliD mutant vaccine
• Target Pathogen: Salmonella spp.
• Target Disease: Salmonellosis
• Product Name: CVD 1923
• Type: Live, attenuated vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Mouse
• clpP from S. typhimurium str. LT2 gene engineering:
  • Type: Gene mutation
  • Description: This guaBA/clpP/fliD mutant is from Salmonella Typhimurium (Tennant et al., 2011).
  • Detailed Gene Information: Click Here.
• fliD gene engineering:
  • Type: Gene mutation
  • Description: This guaBA/clpP/fliD mutant is from Salmonella Typhimurium (Tennant et al., 2011).
  • Detailed Gene Information: Click Here.
• guaA from S. typhimurium str. LT2 gene engineering:
  • Type: Gene mutation
  • Description: This guaBA/clpP/fliD mutant is from Salmonella Typhimurium (Tennant et al., 2011).
  • Detailed Gene Information: Click Here.
• guaB gene engineering:
  • Type: Gene mutation
  • Description: This guaBA/clpP/fliD mutant is from Salmonella Typhimurium (Tennant et al., 2011).
  • Detailed Gene Information: Click Here.
• Immunization Route: Oral immunization

Mouse Response

• Persistence: A guaBA/clpP/fliD mutant is attenuated in mice (Tennant et al., 2011).
• Efficacy: A guaBA/clpP/fliD mutant induces protection in mice from challenge with wild type Salmonella Typhimurium. The vaccine efficacy is 80% (Tennant et al., 2011).
• Host IgG response
  • Description: Immune responses induced included high levels of serum IgG anti-lipopolysaccharide (LPS), with titers increasing progressively during the immunization schedule. Mice immunized with attenuated S. Typhimurium construct CVD 1923 had excellent seroconversion rates after the second immunization and mounted robust antibody responses against both target antigens (LPS and FliC) (Tennant et al., 2011).
  • Detailed Gene Information: Click Here.